Asthma: Commonly used medication shows no clear benefits in children

There are no clear benefits to using long-acting beta2-agonists (LABAs) for treatment of asthma in children, a new study concludes. In an overview of recent Cochrane reviews, Child Health Field researchers report that there is currently insufficient evidence to suggest the drugs, which are recommended to relieve the symptoms of asthma, offer any additional benefit to conventional preventative medications.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news148103953.html">Asthma: Commonly used medication shows no clear benefits in children</a></p> <p>There are no clear benefits to using long-acting beta2-agonists (LABAs) for treatment of asthma in children, a new study concludes. In an overview of recent Cochrane reviews, Child Health Field researchers report that there is currently insufficient evidence to suggest the drugs, which are recommended to relieve the symptoms of asthma, offer any additional benefit to conventional preventative medications.</p>